Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) CFO Charles N. York II sold 1,089 shares of the stock in a transaction on Tuesday, August 16th. The shares were sold at an average price of $24.31, for a total value of $26,473.59. Following the completion of the transaction, the chief financial officer now owns 324,401 shares in the company, valued at $7,886,188.31. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Day One Biopharmaceuticals Stock Performance
Shares of DAWN traded down $0.17 during midday trading on Wednesday, hitting $24.07. The stock had a trading volume of 820,120 shares, compared to its average volume of 834,740. The company has a 50 day simple moving average of $18.26 and a two-hundred day simple moving average of $13.24. Day One Biopharmaceuticals, Inc. has a twelve month low of $5.44 and a twelve month high of $28.70.
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.11). Equities analysts expect that Day One Biopharmaceuticals, Inc. will post -2.18 EPS for the current fiscal year.
Hedge Funds Weigh In On Day One Biopharmaceuticals
Wall Street Analyst Weigh In
DAWN has been the topic of several recent research reports. Piper Sandler raised their price target on Day One Biopharmaceuticals from $35.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday, June 20th. Wedbush raised their price target on Day One Biopharmaceuticals from $32.00 to $35.00 and gave the stock an “outperform” rating in a research report on Monday, June 13th.
Day One Biopharmaceuticals Company Profile
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.
- Get a free copy of the StockNews.com research report on Day One Biopharmaceuticals (DAWN)
- Lowe’s Stands Out Amid Q2 Retail Reports
- Agilent Technologies Proves Its Worth VS Illumina
- Target’s Results Cap Upside Potential For Retail Stocks
- Are These 3 Video Game Stocks Now In Play?
- Why Healthy Retail Sales Numbers Bode Well for Coke and Pepsi
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.